Papillomavirus-Induced Oncogenesis: Current Insights and Future Directions

A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Human Virology and Viral Diseases".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 10501

Special Issue Editors


E-Mail Website
Guest Editor
School of Life Science, Pharmacy and Chemistry, Kingston University London, London, UK
Interests: Human Papillomavirus (HPV); Varizella-Zoster-Virus (VZV)

E-Mail Website
Guest Editor
Professor of Oncology, Head of Memorial Cancer Center, Antalya, Turkey
Interests: cancer biology; clinical oncology; cancer therapeutics; head and neck cancers; Human Papilloma Virus (HPV) related cancers

Special Issue Information

Dear Colleagues,

Papillomaviruses (PVs) encompass a diverse family of viruses, with over 100 identified types, 13 of which are recognized as carcinogenic. These viruses have been implicated in a range of oncogenic processes across various anatomical sites, presenting a complex area of study within the field of virology and oncology. Understanding the underlying mechanisms and clinical implications of papillomavirus-induced oncogenesis is thus of paramount importance.

This Special Issue aims to provide a comprehensive platform for the exploration of current insights and future directions in papillomavirus-induced oncogenesis. We invite contributions covering a wide array of topics, including but not limited to:

  • Elucidating the molecular and cellular mechanisms underpinning papillomavirus-induced oncogenesis, spanning a diverse range of anatomical sites;
  • Advances in the development and application of diagnostic tools and techniques for detecting papillomavirus infections and associated malignancies;
  • Epidemiological studies and analyses of trends in papillomavirus-associated cancers, providing critical insights into the global burden of these malignancies;
  • Innovative therapeutic approaches, including immunotherapies, targeted interventions, and the exploration of potential biomarkers for personalized treatment strategies;
  • Evaluation of vaccination against papillomaviruses, assessing their impact on prevention, risk reduction, and potential applications beyond established indications.

We welcome contributions from researchers, clinicians, and experts in the field, with the aim of fostering a comprehensive understanding of the complex interplay between papillomaviruses and oncogenesis across diverse anatomical contexts. Muharrem Okan Cakir will provide valuable support to the co-editor and editors by participating in manuscript reviews, facilitating effective communication with reviewers, ensuring the maintenance of quality standards, and collating reviewer comments. Additionally, he will be involved in communicating the final decision to the corresponding author. Together, we endeavor to advance knowledge in this critical area of virology and oncology.

Dr. Hossein H. Ashrafi
Prof. Dr. Mustafa Ozdogan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • oncogenesis
  • human papillomavirus (HPV)
  • molecular mechanisms
  • cancer prevention
  • viral oncology
  • novel therapies for HPV-related cancers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (7 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 2168 KiB  
Article
Detection of High-Risk Human Papillomavirus (HPV), p16 and EGFR in Lung Cancer: Insights from the Mediterranean Region of Turkey
by Arsenal Sezgin Alikanoğlu and İrem Atalay Karaçay
Viruses 2024, 16(8), 1201; https://doi.org/10.3390/v16081201 - 26 Jul 2024
Viewed by 736
Abstract
Human papillomavirus (HPV) is an oncogenic DNA virus that plays a role in different cancer types. The aim of this study was to detect the prevalence and types of HPV and its relation with p16, EGFR and clinical findings in lung cancer. HPV [...] Read more.
Human papillomavirus (HPV) is an oncogenic DNA virus that plays a role in different cancer types. The aim of this study was to detect the prevalence and types of HPV and its relation with p16, EGFR and clinical findings in lung cancer. HPV and EGFR detection and genotyping of HPV were performed by polymerase chain reaction (PCR) and p16 by immunohistochemistry. Fifty lung cancer patients and seven patients with non-neoplastic lung disease were enrolled in this study. HPV was positive in 78% (39/50) of lung cancer cases. HPV 51 was the most frequent type, followed by HPV 16. Moreover, p16 was positive in 24% (12/50) of the cancer patients, and all of these patients were HPV-positive, while 27 HPV-positive patients showed no p16 expression. There was no relationship between HPV infection and p16 (p = 0.05), gender (p = 0.42), age (p = 0.38), or smoking history (p = 0.68). Although not statistically significant, the HPV prevalence was found to be higher in cancer patients compared to non-neoplastic patients. The prevalence of HPV in lung cancer varies across different studies, which may be due to differences in the detection methods, number of patients, geographic regions, and vaccination status. Further studies are necessary to understand the role of HPV in lung cancer pathogenesis. Full article
Show Figures

Figure 1

6 pages, 194 KiB  
Communication
Short Communication: Understanding the Barriers to Cervical Cancer Prevention and HPV Vaccination in Saudi Arabia
by Jobran M. Moshi, Aarman Sohaili, Hassan N. Moafa, Ahlam Mohammed S. Hakami, Mohsen M. Mashi and Pierre P. M. Thomas
Viruses 2024, 16(6), 974; https://doi.org/10.3390/v16060974 - 18 Jun 2024
Cited by 1 | Viewed by 1225
Abstract
Cervical cancer, along with other sexual and reproductive health and rights (SRHR) conditions, poses a significant burden in the Kingdom of Saudi Arabia (KSA). Despite the availability of effective preventive methods such as vaccinations, particularly against the Human Papillomavirus (HPV), awareness about such [...] Read more.
Cervical cancer, along with other sexual and reproductive health and rights (SRHR) conditions, poses a significant burden in the Kingdom of Saudi Arabia (KSA). Despite the availability of effective preventive methods such as vaccinations, particularly against the Human Papillomavirus (HPV), awareness about such preventive methods and HPV vaccination remains alarmingly low in the KSA, even with governmental effort and support. While many women are aware of the risks, the uptake of the HPV vaccine remains below 10% (7.6%) at the country level. This highlights the urgent need for Knowledge, Attitude, and Practice (KAP) at the community level to raise awareness, dispel misconceptions, and empower women to embrace vaccinations. Additionally, there is a need to revitalize the cancer registry system to better track and monitor cervical cancer cases. This short communication aims to map these barriers while identifying opportunities for impactful research. Drawing from the scientific literature, government reports, and expert insights, we highlight the challenges surrounding the tackling of HPV. By exploring diverse sources of knowledge, this paper not only highlights current obstacles but also proposes actionable solutions for future interventions. Full article
14 pages, 645 KiB  
Article
Factors Associated with HPV Genital Warts: A Self-Reported Cross-Sectional Study among Students and Staff of a Northern University in Nigeria
by Melvin Omone Ogbolu, Olanrewaju D. Eniade, Hussaini Majiya and Miklós Kozlovszky
Viruses 2024, 16(6), 902; https://doi.org/10.3390/v16060902 - 2 Jun 2024
Cited by 1 | Viewed by 1333
Abstract
The menace of human papillomavirus (HPV) infections among low- and middle-income countries with no access to a free HPV vaccine is a public health concern. HPV is one of the most common sexually transmitted infections (STIs) in Nigeria, while the most known types [...] Read more.
The menace of human papillomavirus (HPV) infections among low- and middle-income countries with no access to a free HPV vaccine is a public health concern. HPV is one of the most common sexually transmitted infections (STIs) in Nigeria, while the most known types of HPV genotypes being transmitted are the high-risk HPV-16 and 18 genotypes. In this study, we explored the predictors of self-reported HPV infections and HPV genital warts infection among a population of students, non-academic staff, and academic staff of Ibrahim Badamasi Babangida (IBB) University located in Lapai, Nigeria. We also assessed their knowledge about HPV infections and genotypes, and sexual behaviors. An online cross-sectional study was conducted by setting up a structured questionnaire on Google Forms and it was distributed to the university community via Facebook and other social media platforms of the university. The form captured questions on HPV infection, and knowledge about HPV infection and genotypes, as well as the sexual health of the participants. All variables were described using frequencies and percentage distribution; chi-squared test statistics were used to explore the association between HPV infection (medical records of HPV infection) and the participants’ profile, and a logistic regression analysis was performed to examine the factors associated with HPV genital warts infection among the population. This study reveals those participants between the ages of 26–40 years (81.3%) and those currently not in a sexually active relationship—single/divorced (26.4%)—who have self-reported having the HPV-16 and -18 genotypes. Moreover, participants between 26–40 years of age (OR: 0.45, 95%CI: 0.22–0.89) reported themselves to be carriers of HPV genital warts. Therefore, this study reveals the factors associated with HPV infection and genital warts peculiar to IBB university students and staff. Hence, we suggest the need for HPV awareness programs and free HPV vaccine availability at IBB university. Full article
Show Figures

Figure 1

12 pages, 2828 KiB  
Article
Findings and Challenges in Replacing Traditional Uterine Cervical Cancer Diagnosis with Molecular Tools in Private Gynecological Practice in Mexico
by José L. Castrillo-Diez, Carolina Rivera-Santiago, Silvia M. Ávila-Flores, Silvia A. Barrera-Barrera and Hugo A. Barrera-Saldaña
Viruses 2024, 16(6), 887; https://doi.org/10.3390/v16060887 - 31 May 2024
Viewed by 752
Abstract
We have been encouraging practicing gynecologists to adopt molecular diagnostics tests, PCR, and cancer biomarkers, as alternatives enabled by these platforms, to traditional Papanicolaou and colposcopy tests, respectively. An aliquot of liquid-based cytology was used for the molecular test [high-risk HPV types, (HR [...] Read more.
We have been encouraging practicing gynecologists to adopt molecular diagnostics tests, PCR, and cancer biomarkers, as alternatives enabled by these platforms, to traditional Papanicolaou and colposcopy tests, respectively. An aliquot of liquid-based cytology was used for the molecular test [high-risk HPV types, (HR HPV)], another for the PAP test, and one more for p16/Ki67 dual-stain cytology. A total of 4499 laboratory samples were evaluated, and we found that 25.1% of low-grade samples and 47.9% of high-grade samples after PAP testing had a negative HR HPV-PCR result. In those cases, reported as Pap-negative, 22.1% had a positive HR HPV-PCR result. Dual staining with p16/Ki67 biomarkers in samples was positive for HR HPV, and 31.7% were also positive for these markers. Out of the PCR results that were positive for any of these HR HPV subtypes, n 68.3%, we did not find evidence for the presence of cancerous cells, highlighting the importance of performing dual staining with p16/Ki67 after PCR to avoid unnecessary colposcopies. The encountered challenges are a deep-rooted social reluctance in Mexico to abandon traditional Pap smears and the opinion of many specialists. Therefore, we still believe that colposcopy continues to be a preferred procedure over the dual-staining protocol. Full article
Show Figures

Figure 1

13 pages, 2117 KiB  
Article
HPV16 E6 Oncogene Contributes to Cancer Immune Evasion by Regulating PD-L1 Expression through a miR-143/HIF-1a Pathway
by Georgios Konstantopoulos, Danai Leventakou, Despoina-Rozi Saltiel, Efthalia Zervoudi, Eirini Logotheti, Spyros Pettas, Korina Karagianni, Angeliki Daiou, Konstantinos E. Hatzistergos, Dimitra Dafou, Minas Arsenakis and Christine Kottaridi
Viruses 2024, 16(1), 113; https://doi.org/10.3390/v16010113 - 12 Jan 2024
Cited by 1 | Viewed by 2308
Abstract
Human Papillomaviruses have been associated with the occurrence of cervical cancer, the fourth most common cancer that affects women globally, while 70% of cases are caused by infection with the high-risk types HPV16 and HPV18. The integration of these viruses’ oncogenes E6 and [...] Read more.
Human Papillomaviruses have been associated with the occurrence of cervical cancer, the fourth most common cancer that affects women globally, while 70% of cases are caused by infection with the high-risk types HPV16 and HPV18. The integration of these viruses’ oncogenes E6 and E7 into the host’s genome affects a multitude of cellular functions and alters the expression of molecules. The aim of this study was to investigate how these oncogenes contribute to the expression of immune system control molecules, using cell lines with integrated HPV16 genome, before and after knocking out E6 viral gene using the CRISPR/Cas9 system, delivered with a lentiviral vector. The molecules studied are the T-cell inactivating protein PD-L1, its transcription factor HIF-1a and the latter’s negative regulator, miR-143. According to our results, in the E6 knock out (E6KO) cell lines an increased expression of miR-143 was recorded, while a decrease in the expression of HIF-1a and PD-L1 was exhibited. These findings indicate that E6 protein probably plays a significant role in enabling cervical cancer cells to evade the immune system, while we propose a molecular pathway in cervical cancer, where PD-L1’s expression is regulated by E6 protein through a miR-143/HIF-1a axis. Full article
Show Figures

Figure 1

Review

Jump to: Research

44 pages, 1007 KiB  
Review
Looking Back, Moving Forward: Challenges and Opportunities for Global Cervical Cancer Prevention and Control
by Philip E. Castle
Viruses 2024, 16(9), 1357; https://doi.org/10.3390/v16091357 - 25 Aug 2024
Viewed by 995
Abstract
Despite the introduction of Pap testing for screening to prevent cervical cancer in the mid-20th century, cervical cancer remains a common cause of cancer-related mortality and morbidity globally. This is primarily due to differences in access to screening and care between low-income and [...] Read more.
Despite the introduction of Pap testing for screening to prevent cervical cancer in the mid-20th century, cervical cancer remains a common cause of cancer-related mortality and morbidity globally. This is primarily due to differences in access to screening and care between low-income and high-income resource settings, resulting in cervical cancer being one of the cancers with the greatest health disparity. The discovery of human papillomavirus (HPV) as the near-obligate viral cause of cervical cancer can revolutionize how it can be prevented: HPV vaccination against infection for prophylaxis and HPV testing-based screening for the detection and treatment of cervical pre-cancers for interception. As a result of this progress, the World Health Organization has championed the elimination of cervical cancer as a global health problem. However, unless research, investments, and actions are taken to ensure equitable global access to these highly effective preventive interventions, there is a real threat to exacerbating the current health inequities in cervical cancer. In this review, the progress to date and the challenges and opportunities for fulfilling the potential of HPV-targeted prevention for global cervical cancer control are discussed. Full article
Show Figures

Figure 1

16 pages, 1136 KiB  
Review
Unveiling the Role of Human Papillomavirus in Urogenital Carcinogenesis a Comprehensive Review
by Beliz Bahar Karaoğlan and Yüksel Ürün
Viruses 2024, 16(5), 667; https://doi.org/10.3390/v16050667 - 25 Apr 2024
Viewed by 1714
Abstract
Human papillomavirus (HPV), an oncogenic DNA virus, is the most common sexually transmitted virus and significant public health concern globally. Despite the substantial prevalence of HPV infection among men, routine testing remains elusive due to the lack of approved HPV tests and the [...] Read more.
Human papillomavirus (HPV), an oncogenic DNA virus, is the most common sexually transmitted virus and significant public health concern globally. Despite the substantial prevalence of HPV infection among men, routine testing remains elusive due to the lack of approved HPV tests and the complexity of detection methods. Various studies have explored the link between HPV and genitourinary cancers, revealing different associations influenced by geographic variation, histological subtype and methodological differences. These findings underscore the importance of further research to elucidate the role of HPV in male urogenital cancers. This comprehensive review delves into the intricate relationship between HPV and male genitourinary cancers, shedding light on the virus’s oncogenic mechanisms and its reported prevalence. A deeper understanding of HPV’s implications for male health is essential for advancing public health initiatives and reducing the burden of urogenital cancers worldwide. Full article
Show Figures

Figure 1

Back to TopTop